FDA Alerts: Severe Itching Risk After Stopping Long-Term Use of Cetirizine or Levocetirizine
What’s the Issue? On May 16, 2025, the FDA issued a Drug Safety Communication warning that discontinuation of cetirizine (Zyrtec) or levocetirizine (Xyzal)—after long-term,…
Read more →Breaking: Amneal Issues Nationwide Recall of Sulfamethoxazole/Trimethoprim Tablets Due to Microbial Contamination
What’s Being Recalled? On June 2, 2025, Amneal Pharmaceutical LLC initiated a nationwide recall of three specific lots of Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80…
Read more →FDA Adds Heat-Risk Warning to Transderm Scōp (Scopolamine Patch): What Patients, Clinicians, and Manufacturers Need to Know
What happened (and when)? On June 18, 2025, the U.S. FDA issued a Drug Safety Communication requiring new warnings for the anti-nausea patch Transderm…
Read more →FDA Mandates New Warnings on Extended-Release ADHD Stimulants
What’s Changing? On June 30, 2025, the U.S. Food and Drug Administration (FDA) issued a safety communication requiring all manufacturers of extended-release (ER) stimulants—including…
Read more →FDA is Requiring Opioid Pain Medicine Manufacturers to Update Prescribing Information Regarding Long-Term Use: Drug Safety Communication
Breaking Down the FDA’s Latest Mandate on Opioid Labeling What’s Going On? On July 31, 2025, the FDA released a class-wide Drug Safety Communication…
Read more →Mispackaged Antibiotics: An Investigative Spotlight on Sandoz’s Nationwide Recall
A Critical Mix-Up: What Exactly Happened On June 27, 2025, Sandoz Inc. initiated a voluntary nationwide recall of a single lot of Cefazolin for…
Read more →